𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mechanisms of Neuroprotective Effects of Therapeutic Acetylcholinesterase Inhibitors Used in Treatment of Alzheimer′s Disease

✍ Scribed by Yuki Takatori

Publisher
John Wiley and Sons
Year
2006
Weight
8 KB
Volume
37
Category
Article
ISSN
0931-7597

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advances in the development of kinase in
Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease
✍ Mary J. Savage; Diane E. Gingrich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

## Abstract Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid β peptide (Aβ). Recent clinical trial results question the efficacy of targeting Aβ for treatment of mild to moderate AD, highli

Review of drug development and therapeut
Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease
✍ John J. Sramek; Victoria Zarotsky; Neal R. Cutler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

## Abstract Researchers have for some time appreciated the role of the neurotransmitter acetylcholine in Alzheimer's disease, and have realized the development of a number of acetylcholinesterase inhibitors. Bridging and dynabridging studies have played an important role in the development of these

The effects of galantamine treatment on
The effects of galantamine treatment on caregiver time in Alzheimer's disease
✍ Mary Sano; Gordon K. Wilcock; Bart van Baelen; Shane Kavanagh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## Aim The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers. ## Methods Data were pooled from two concurrent, multi‐centre, randomized, double‐blind, placebo‐controlled, 6‐month trials